Expert Review of Hematology, Год журнала: 2024, Номер unknown
Опубликована: Ноя. 29, 2024
COVID-19 is a continuing challenge for immunocompromised patients with hematological malignancies. Such are at increased risk complications, including hospitalization, respiratory failure, delay of anti-cancer therapies, and even death. In addition to non-pharmacologic interventions, the main strategies prevention in such vaccination pre-exposure prophylaxis.
Язык: Английский
Expert Review of Anti-infective Therapy, Год журнала: 2025, Номер unknown
Опубликована: Фев. 25, 2025
The success in the COVID-19 pandemic containment largely originated from vaccine- and infection-elicited immunity, with SARS-CoV-2 infection only marginally mitigated by availability of antiviral drugs. current lack effective prophylactic therapeutic agents immunocompromised patients highlights need for a radical change design both drug manufacturing clinical trials. In this review authors summarize their suggestions manufacturers, reviewing classes small molecule antivirals passive immunotherapies highlighting limitations unexploited potential. Molecular serological testing can improve appropriateness. Efficacy be improved combining different while preserving economical sustainability. Respiratory delivery should better investigated
Язык: Английский
Процитировано
0
Опубликована: Ноя. 22, 2023
Since late 2019, COVID-19, a severe acute respiratory syndrome pandemic, was caused by the new SARS-CoV-2 virus belonging to Coronaviridae family, . Several antiviral therapies, mostly derived from previous epidemics, were initially repurposed fight this not rarely life-threatening illness. Among them, however, only specific antibody-based therapy available against infection during first year of pandemic represented COVID-19 convalescent plasma (CCP). CCP, collected recovered individuals, contains high levels polyclonal antibodies different subclasses able neutralize infection. Tens randomized controlled trials have been conducted last three years evaluate safety and clinical efficacy CCP in both hospitalized ambulatory patients, whose main results will be summarized narrative review. In addition, we present current knowledge on development anti-SARS-CoV-2 hyperimmune immunoglobulins.
Язык: Английский
Процитировано
4
Transfusion, Год журнала: 2024, Номер 64(8), С. 1588 - 1589
Опубликована: Авг. 1, 2024
Язык: Английский
Процитировано
0
Expert Review of Hematology, Год журнала: 2024, Номер unknown
Опубликована: Ноя. 29, 2024
COVID-19 is a continuing challenge for immunocompromised patients with hematological malignancies. Such are at increased risk complications, including hospitalization, respiratory failure, delay of anti-cancer therapies, and even death. In addition to non-pharmacologic interventions, the main strategies prevention in such vaccination pre-exposure prophylaxis.
Язык: Английский
Процитировано
0